Celebrating
25 Years Of Practice

Philips CPAP, BiPAP, And Ventilator Investigation

Goldenberg Schneider is currently investigating the Dutch medical equipment company Philips, which recently recalled sleep apnea machines – including Continuous Positive Airway Pressure (CPAP), Bilevel Positive Airway Pressure (BiPAP) machines — and ventilators due to users’ increased risk of developing cancer, pulmonary fibrosis, and other injuries such as headaches, irritation, inflammation, and respiratory issues.

On June 14, 2021, Philips announced a recall of many of its CPAP and BiPAP machines, which are used to treat sleep apnea, and ventilators, which treat respiratory failure. The recalled products contain polyester-based polyurethane (PE-PUR) foam for sound abatement. It has now been revealed that the PE-PUR foam may break down and be inhaled or ingested and may emit volatile organic compounds (VOCs) resulting in adverse effects to organs, and even cancer. In an announcement to doctors, Philips explained that these hazards could result in “serious injury which can be life-threatening or cause permanent impairment.”

Sleep apnea is a sleeping disorder in which breathing is disturbed temporarily during sleep. Breathing may stop or become very shallow. This may be associated with fatigue, daytime sleepiness, interrupted sleep, or snoring, among other symptoms. Serious cases can lead to hypertension, heart attack, or stroke, among other medical ailments. CPAP therapy is a common treatment for sleep apnea. In CPAP therapy, a machine delivers a flow of air through a mask over the nose or mouth, which increases air pressure in the throat so that the airway does not collapse during inhalation. CPAP therapy assists breathing during sleep and can successfully treat sleep apnea

If you or anyone you know purchased a Philips CPAP, BiPAP, or ventilator and would like additional information about your legal rights, we would be pleased to discuss the matter with you. You can contact the attorneys at Goldenberg Schneider, LPA, by calling 513-982-1569 or sending an email to [email protected].